News & Updates
Search Research Content
Resource Finder at Kennedy Krieger Institute
A free resource that provides access to information and support for individuals and families living with developmental disabilities.
Bromocriptine reduces steatosis in obese rodent models.
|Title||Bromocriptine reduces steatosis in obese rodent models.|
|Publication Type||Journal Article|
|Year of Publication||2006|
|Authors||Davis LM, Pei Z, Trush MA, Cheskin LJ, Contoreggi C, McCullough K, Watkins PA, Moran TH|
|Journal||Journal of hepatology|
|Date Published||2006 Sep|
Obesity is a risk factor for glucose intolerance, steatosis, and oxidative stress, characteristics of nonalcoholic fatty liver disease. Bromocriptine may have anti-obesity, insulin-sensitizing, lipolytic, and antioxidant properties. We, therefore, hypothesized that bromocriptine would improve markers of nonalcoholic fatty liver disease in obese rodent models.
|Alternate Journal||J. Hepatol.|